Drug Type Bispecific antibody |
Synonyms- |
Target |
Mechanism CD3 modulators(T cell surface glycoprotein CD3 modulators), MSLN inhibitors(Mesothelin inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseDiscovery |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Discovery | - | 09 Feb 2022 |